Can Blood Tests Predict Kidney Damage in Sepsis? A Study on Platelet-Albumin Ratio and NGAL

Not yet recruiting

• Conditions: Acute kidney failure, unspecified,

• Registration Number: CTRI/2025/05/087535
• Lead Sponsor: AIIMS Jodhpur

Brief Summary

My study, "A Comparison of Platelet-to-Albumin Ratio and Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL)to Predict AKI in Patients with Sepsis," An observational study will be carriedout in the Adult Intensive Care Unit of All India Institute of Medical Sciences, the study will include all patients of age >= 18 years with sepsis. Patientswith repeated ICU admission and pre-existing renal disease shall be excluded.The research question is to find out whether PAR has a similar diagnostic andprognostic value as serum NGAL to predict AKI.

The study aims to investigate the role of PAR andurinary NGAL in predicting AKI in patients admitted to the ICU with sepsis. Theexpected outcome is to define an optimum cut-off value of PAR andserum NGAL for diagnosing sepsis & to prognosticate the outcome of sepsis,which helps in the early identification of AKI and thus early intervention andmanagement.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-05-06
• Last Update Posted: 2025-05-23

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Inclusion criteria: 1.Patients with sepsis 2.Age more than 18 years.

Exclusion Criteria

Exclusion criteria: 1.Multiple ICU admissions 2.Pre-existing renal disease 3.Missing data.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the role of PAR and serum NGAL in predicting AKI in patients with sepsis admitted to ICU	At the time of admission (baseline) and at the time of development of acute kidney injury (AKI) according to KDIGO criteria

Secondary Outcome Measures

Name	Time	Method
1. To establish an optimum cut-off value for PAR & serum NGAL for diagnosing sepsis & to prognosticate the outcome of sepsis.	2. Evaluation of the combined value of PAR & NGAL for predicting the development of AKI in sepsis

Trial Locations

Locations (1)

AIIMS Jodhpur; 🇮🇳 Jodhpur, RAJASTHAN, India

AIIMS Jodhpur

🇮🇳Jodhpur, RAJASTHAN, India

Dr Aishwary Shivhare

Principal investigator

9901887223

aishwary2017shivhare@gmail.com